Sun recalls cancer drug

Share this article:

Sun Pharmaceuticals has racked up its second recall of the year. Reuters reports that the drugmaker has recalled 200 vials of the cancer drug gemcitabine which were distributed in the US. Reuters notes that the voluntary recall, which started in April, was in the “Class II” category which means potential adverse reactions would be temporary.

The generics maker, which recently purchased beleaguered Ranbaxy Pharmaceuticals, recalled 2,528 bottles of its generic Glumetza diabetes drug earlier this year after a patient found epilepsy medication in his bottle.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.